TriangleNCT01520909 · CITED IN SOURCE DOCUMENTS
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2015-03-10
The purpose of this study is to investigate the efficacy, safety and tolerability of eltrombopag in children with previously treated chronic immune thrombocytopenia who are between 1 and 17 years of age. This is a 2 part study. In part 1, patients will be randomized to receive either eltrombopag or placebo for 13 weeks. All patients who complete part 1 will enter part 2. In part 2, all patients will receive 24 weeks of eltrombopag.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1
Percentage of Responders
Number of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 12 Weeks of Part 1
Number of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 6 Weeks of Part 1
Weighted Mean Platelet Count
Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the First 12 Weeks of Part 1
Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 1
Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 1
Number of Participants Who Achieved a Platelet Count >=50 Gi/L at Any Time During Part 2
Number of Weeks in Which Participants Achieved a Platelet Count >=50 Gi/L, Between Weeks 4 and 24 of Part 2
Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During Part 2
Number of Participants Who Reduced or Discontinued Baseline Concomitant ITP Medications During Part 2 Without Requiring Subsequent Rescue Therapy
Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 2
Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the WHO Bleeding Scale During Part 2
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 1
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2
Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline During Part 1
Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline During Part 2
Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Hematology Parameters at Any Time Post-Baseline During Part 1
Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Hematology Parameters at Any Time Post-Baseline During Part 2
Number of Participants With Vital Sign Data Falling Outside the Reference Ranges (RR) at the Indicated Visit During Part 1
Number of Participants With Vital Sign Data Falling Outside the Reference Ranges (RR) at the Indicated Visit During Part 2
Number of Participants With a Change in Visual Acuity Since Baseline at Week 12 of Part 1
Number of Participants With a Change in Visual Acuity Since Baseline at Week 24 of Part 2
Number of Participants With a Change in Visual Acuity Since Baseline at Follow-Up Week 24
Number of Participants With Worsening Visual Acuity Due to Cataracts at Week 12 of Part 1
Number of Participants With Worsening Visual Acuity Due to Cataracts at Week 24 of Part 2
Number of Participants With Worsening Visual Acuity Due to Cataracts at Follow-Up Week 24
Pharmacokinetic (PK) Assessments for Eltrombopag for AUC (0-t)
Pharmacokinetic (PK) Assessments for Eltrombopag for Cmax
Pharmacokinetic (PK) Assessments for Eltrombopag for Apparent Oral Clearance (CL/F) and Apparent Intercompartmental Clearance (Q/F)
PK Assessments for Eltrombopag for Apparent Central Volume (Vc/F) and Apparent Peripheral Volume (Vp/F)
Population PK Model Point Estimate for Eltrombopag for Absorption Rate-constant (Ka)
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Written informed consent must be obtained from the patient's guardian and accompanying informed assent from the patient (for children over 6 years old) * Patients must be between 1 year and \<18 years of age at Day 1 * Patients will have a confirmed diagnosis of chronic ITP for at least 1 year, at screening, according to the guidelines published in the International Working Group Report * A peripheral blood smear or bone marrow examination will support the diagnosis of ITP with no evidence of other causes of thrombocytopenia. * Patients must be refractory or have relapsed after at least one prior ITP therapy, or patients must be unable, for a medical reason, to continue other ITP treatments. * Patients must have a Day 1 (or within 48 hours prior) platelet count \<30 Gi/L. * Previous therapy for ITP with immunoglobulins (IVIg and anti-D) must have been completed at least 2 weeks prior to Day 1, or these therapies must have been completed at least 1 week prior to Day 1 and have been clearly ineffective. * Previous treatment for ITP with splenectomy, rituximab and cyclophosphamide must have been completed at least 4 weeks prior to Day 1. * Patients treated with concomitant ITP medication (e.g. corticosteroids or azathioprine) must be receiving a dose that has been stable for at least 4 weeks prior to Day 1. * Patients must have a complete blood count (CBC) not suggestive of another hematological disorder. * Patients must have the following laboratory results: * prothrombin time international normalized ratio (INR) and activated partial thromboplastin time (aPTT) within 80 to 120% of the normal range. * clinical chemistries that do NOT exceed the upper limit of normal reference range by more than 20% for the following: creatinine, ALT, AST, total bilirubin, and alkaline phosphatase. * total albumin that is not below the lower limit of normal by more than 10%. * Female patients of child-bearing potential (after menarche) must: * have a negative pregnancy test within 24 hours of first dose of study treatment, * agree and be able to provide a blood or urine specimen for pregnancy testing during the study, * agree to use effective contraception during the study and for 28 days following the last dose of study treatment, and not be lactating. * Male patients with a female partner of childbearing potential must agree to use effective contraception from 2 weeks prior to administration of the first dose of study treatment until 3 months after the last dose of study treatment. * In France, a patient will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category. Exclusion Criteria: * Patients with any clinically relevant abnormality, other than ITP, identified on the screening examination or any other medical condition or circumstance, which in the opinion of the investigator makes the patient unsuitable for participation in the study or suggests another primary diagnosis (e.g. Thrombocytopenia is secondary to another disease). * Patients with concurrent or past malignant disease, including myeloproliferative disorder. * Patients expected not to be suitable for continuation of their current therapy for at least 13 additional weeks. * Patients with a history of platelet agglutination abnormality that prevents reliable measurement of platelet counts. * Patients with a diagnosis of secondary immune thrombocytopenia, including those with laboratory or clinical evidence of HIV infection, anti-phospholipid antibody syndrome, chronic hepatitis B infection, hepatitis c virus infection, or any evidence of active hepatitis at the time of subject screening. * Patients with Evans syndrome (autoimmune thrombocytopenia and autoimmune hemolysis). * Patients with known inherited thrombocytopenia (e.g. MYH9 disorders). * Patients treated with any medication that affects platelet function (including but not limited to aspirin, clopidogrel and/or NSAIDS) or anti-coagulants for \>3 consecutive days within 2 weeks of Day 1. * Patients who have received treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding Day 1. * Patients who have previously received eltrombopag or any other thrombopoietin receptor agonist. * Any patient considered to be a child in care, defined as one who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation. This can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above. The definition of a child in care does not include a child who is adopted or who has an appointed legal guardian. * Patients who have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to eltrombopag or excipients that contraindicates their participation. * Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions that could interfere with the patient's safety or compliance to the study procedures.
- healthy Volunteers
- false
- maximum Age
- 17 Years
- minimum Age
- 1 Year
- sex
- ALL
- std Ages
- CHILD
Treatment arms and interventions
- arm Groups
- description
- Part 1, double-blind treatment group
- intervention Names
- Drug: Eltrombopag
- label
- Eltrombopag plus standard of care
- type
- EXPERIMENTAL
- description
- Part 1, double-blind treatment group
- intervention Names
- Drug: Placebo
- label
- Placebo plus standard of care
- type
- PLACEBO_COMPARATOR
- description
- Part 2, open-label
- intervention Names
- Drug: Eltrombopag
- label
- Eltrombopag plus standard of care (Part 2 open-label)
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Eltrombopag plus standard of care
- Eltrombopag plus standard of care (Part 2 open-label)
- description
- Thrombopoietin receptor agonist
- name
- Eltrombopag
- type
- DRUG
- arm Group Labels
- Placebo plus standard of care
- description
- Placebo with no active pharmaceutical ingredient
- name
- Placebo
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- QUADRUPLE
- who Masked
- PARTICIPANT
- CARE_PROVIDER
- INVESTIGATOR
- OUTCOMES_ASSESSOR
- primary Purpose
- TREATMENT
Enrollment
- count
- 92
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Participants who achieved a platelet count \>=50 Gi/L for at least 6 out of 8 weeks, between Weeks 5 and 12 of Part 1, were reported.
- measure
- Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1
- time Frame
- From Week 5 up to Week 12 of Part 1
- secondary Outcomes
- description
- Percentage of participants who responded (defined as platelet count \>= 50 Gi/L in absence of rescue) at least once up to week 12 of Part 1 (Odds of achieving a platelet count \>=50 Gi/L during the first 12 weeks of Part 1)
- measure
- Percentage of Responders
- time Frame
- From Week 1 up to Week 12 of Part 1
- description
- Participants who achieved a platelet count \>=50 Gi/L at any time during the first 12 weeks of Part 1 were reported.
- measure
- Number of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 12 Weeks of Part 1
- time Frame
- From Baseline up to Week 12 of Part 1
- description
- Participants who achieved a platelet count \>=50 Gi/L at any time during the first 6 weeks of Part 1 were reported.
- measure
- Number of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 6 Weeks of Part 1
- time Frame
- From Baseline up to Week 6 of Part 1
- description
- The weighted mean platelet count is defined as "the area under the platelet-time curve divided by the duration of the study (12 weeks)". Weighted mean platelet counts from baseline to week 12 of the randomized period was compared between placebo and eltrombopag using an analysis of covariance model (ANCOVA) adjusting for baseline platelet count and age cohort. For each subject the area between two adjacent visits with platelet counts was calculated. The area was calculated for all pairs of adjacent visits starting at Day 1 of randomized period and then the total sum of all the areas was divided by the total duration of time during the randomized period. For each subject, this method calculates an 'average' platelet count and it allows the possibility that subjects may have had different number of assessments during different times relative to baseline.
- measure
- Weighted Mean Platelet Count
- time Frame
- Baseline and Week 12 of Part 1
- description
- The maximum duration for which a participant continuously maintained a platelet count \>=50 Gi/L was calculated and summarized for the first 12 weeks of Part 1. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If a participant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day.
- measure
- Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the First 12 Weeks of Part 1
- time Frame
- From Baseline up to Week 12 of Part 1
- description
- Rescue treatment is defined as either a new immune (idiopathic) thrombocytopenic purpura (ITP) medication, an increase in the dose of a concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy.
- measure
- Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 1
- time Frame
- From Baseline up to Week 12 of Part 1
- description
- The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross bleeding; Grade 4=debilitating blood loss. The WHO grades were dichotomized into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. Baseline was defined as the Day 1 assessment or the latest possible screening assessment.
- measure
- Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 1
- time Frame
- From Baseline through Follow-up of Part 1
- description
- Participants who achieved a platelet count \>=50 Gi/L at any time during Part 2 (up to Week 24) were reported.
- measure
- Number of Participants Who Achieved a Platelet Count >=50 Gi/L at Any Time During Part 2
- time Frame
- From Baseline up to Week 24 of Part 2
- description
- Platelet response was analyzed after Week 4 for the eltrombopag-only period to allow participants who had been randomized to placebo in the Randomized Period time to escalate to their optimal dose of eltrombopag. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If the participant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day.
- measure
- Number of Weeks in Which Participants Achieved a Platelet Count >=50 Gi/L, Between Weeks 4 and 24 of Part 2
- time Frame
- From Week 4 up to Week 24 of Part 2
- description
- The maximum duration for which a participant continuously maintained a platelet count of \>=50 Gi/L was calculated and summarized for the 24 weeks of eltrombopag dosing (Part 2). Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If the participant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day.
- measure
- Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During Part 2
- time Frame
- From Baseline up to Week 24 of Part 2
- description
- Participants who discontinued or had a sustained reduction of a baseline immune (idiopathic) thrombocytopenic purpura (ITP) medication during the 24 weeks of Part 2 (Open-Label Period) and without requiring subsequent rescue therapy. For participants randomized to placebo in Part 1, Baseline is defined as Week 13 of Part 1. For participants randomized to eltrombopag in Part 1, Baseline is defined as Day 1 of Part 1. A sustained reduction was defined as a reduction for 4 weeks or more.
- measure
- Number of Participants Who Reduced or Discontinued Baseline Concomitant ITP Medications During Part 2 Without Requiring Subsequent Rescue Therapy
- time Frame
- From Baseline up to Week 24 of Part 2
- description
- Rescue treatment was defined as either a new immune (idiopathic) thrombocytopenic purpura (ITP) medication, an increase in the dose of a concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy.
- measure
- Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 2
- time Frame
- From Baseline up to Week 24 of Part 2
Full study description
- brief Summary
- The purpose of this study is to investigate the efficacy, safety and tolerability of eltrombopag in children with previously treated chronic immune thrombocytopenia who are between 1 and 17 years of age. This is a 2 part study. In part 1, patients will be randomized to receive either eltrombopag or placebo for 13 weeks. All patients who complete part 1 will enter part 2. In part 2, all patients will receive 24 weeks of eltrombopag.
- detailed Description
- This is a two part, double-blind, randomized, placebo-controlled and open-label Phase III study to investigate the efficacy, safety and tolerability of eltrombopag in pediatric patients with previously treated chronic ITP. In Part 1, patients will be randomized to receive eltrombopag or placebo in a 13-week double-blind, placebo-controlled treatment period. After completing Part 1, patients will begin Part 2, in which they will receive eltrombopag in an open-label manner during a 24-week treatment period.
Source references
- references
- citation
- Wire MB, Li X, Zhang J, Sallas W, Aslanis V, Ouatas T. Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia. Clin Pharmacol Ther. 2018 Dec;104(6):1199-1207. doi: 10.1002/cpt.1066. Epub 2018 Apr 17.
- pmid
- 29536526
- type
- DERIVED
- citation
- Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015 Oct 24;386(10004):1649-58. doi: 10.1016/S0140-6736(15)61107-2. Epub 2015 Jul 28.
- pmid
- 26231455
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-3ab9e80ca8219d7315aa
- requested nct id
- NCT01520909
- primary nct id
- NCT01520909
- source kind
- fda_spl_label
- source record id
- b8a1cc48-9aaf-486a-9305-090acccb5c02
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- e03f2873f8edd30d929779dee2958bd247c575612a05ce4491a329f065f7910a
- payload
- application numbers
- NDA022291
- NDA207027
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-3ab9e80ca8219d7315aa
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01520909
- occurrences
- context exact
- y. The dose of PROMACTA was reduced if the platelet count exceeded 200 x 10 9 /L and interrupted and reduced if it exceeded 400 x 10 9 /L. In the PETIT2 study (NCT01520909), patients refractory or relapsed to at least one prior ITP therapy with a platelet count less than 30 x 10 9 /L (n = 92) were stratified by age and randomized
- end
- 7227
- exact text
- NCT01520909
- start
- 7216
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/22/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- b8a1cc48-9aaf-486a-9305-090acccb5c02
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- a20476f81499eaadcb663d2457610e22126a4bc539ff02f3708748bd8a52b5b2
- spl effective time
- 20251218
- spl set id
- 7714a0ed-34bb-46e6-a0a5-b363908b22c2
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-5799804a5c78f825f2f0
- requested nct id
- NCT01520909
- primary nct id
- NCT01520909
- source kind
- fda_spl_label
- source record id
- 6a49af27-c1fc-4b62-8c30-fb27bc4c5a3e
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- payload sha256
- 7f19c20251000a91085aa92b7f0e7d1aee1122da183328432f79cab722f3066c
- payload
- application numbers
- NDA216774
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-5799804a5c78f825f2f0
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01520909
- occurrences
- context exact
- The dose of eltrombopag was reduced if the platelet count exceeded 200 x 10 9 /L and interrupted and reduced if it exceeded 400 x 10 9 /L. In the PETIT2 study (NCT01520909), patients refractory or relapsed to at least one prior ITP therapy with a platelet count less than 30 x 10 9 /L (n = 92) were stratified by age and randomized
- end
- 7883
- exact text
- NCT01520909
- start
- 7872
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00400.json
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source json pointer
- /results/26/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 6a49af27-c1fc-4b62-8c30-fb27bc4c5a3e
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 2489e59675590c985cc57ea1c1dd6faf4d44f2d73e6e584bcf6e19c70532f8a2
- spl effective time
- 20260101
- spl set id
- ed51e463-7a03-4858-bbd2-882ce4753d5a
Preserved source evidence · Not medical advice